This list reflects information regarding the supplements as of the approval date. It is not updated with regard to applicant or application status changes. The supplements are listed by date of approval, with the most recent action at the top.
|Tradename/Proper Name||Indication for Use||STN||Manufacturer/
Rabies Immune Globulin (Human)
|1. Submit the Final Study Report for the Required Pediatric Assessment as agreed to in Postmarketing Requirement #1 in Kamada's August 23, 2017 BLA approval letter (STN BL 125613/0) and,
2. Update the prescribing information.
1555 King Street
Alexandria, VA 22314
Lic. # 1826
Immune Globulin Subcutaneous (Human), 20% Liquid
|To update the Dosage and Administration, Adverse Reactions and Clinical Studies sections of the US Prescribing Information based on the results from Study IgPro20_3004, open-label extension study that investigated the long-term safety and efficacy of the product in the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).||125350/969||CSL Behring AG
CSL Behring LLC
1020 First Avenue
King of Prussia, PA 19406-0901
Lic. # 1766
|To update the existing United States Prescribing Information (USPI) for YESCARTA with safety results from the Phase 2 Safety Management Cohort 4 from Study ZUMA-1, which assessed the effect of earlier intervention with corticosteroids and/or tocilizumab on the incidence and severity of CRS and neurologic events.||125643/231||Kite Pharma Inc.
Santa Monica, CA 90404
Lic. # 2064
Short Ragweed Pollen Allergen Extract
|For use in children and adolescents 5 to 17 years of age. Short Ragweed Pollen Allergen Extract is indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in persons 5 through 65 years of age.||125478/293||ALK-Abello A/S
135 Route 202/206 Suite 3
Bedminster, NJ 20879
Lic. # 1292
|To include a new indication for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.||125643/248||Kite Pharma, Inc.
Santa Monica, CA 90404
Lic. # 2064
|To extend the use of FLUCELVAX QUADRIVALENT manufactured at the Holly Springs, NC and -------(b)(4)------ facilities to persons 2 years of age and older.||125408/329||Seqirus Inc.
50 Hampshire Street, 9th Floor
Cambridge, MA 02139
Lic. # 2049
Immune Globulin Intravenous (Human)-ifas 10%
|Include the following: 1. a new indication for the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment, and
2. to remove the distinction between new and experienced patients in section 2.1 in the prescribing information label.
|125587/70||Octapharma Pharmazeutika Produktionsges.m.b.H
117 West Century Rd.
Paramus, NJ 07652
Lic. # 1646
Antihemophilic Factor (Recombinant), Full Length
|To provide the Clinical Study Report (CSR) for Postmarketing Commitment #1 noted in the approval letter for STN BL 125574/0 and to update Section 6 of the Prescribing Information to include information related to inhibitor development in previously untreated patients with hemophilia A.||125574/400||Bayer HealthCare LLC
100 Bayer Boulevard
P.O. Box 915
Whippany, NJ 07981-0915
Lic. # 0008